You need to know the price of Genotropin 12mg (Somatropin 36IU) growth hormone how much? You do not know the drug Genotropin 12mg sold where? index-china is a specialized trading site for Genotropin Growth Hormone 12mg Somatropin 36IU in Ho Chi Minh City, Hanoi, Danang, Can Tho … and nationwide.
Genotropin medicine 12mg Somatropin 36IU growth hormone
- Brand name: Genotropin 12mg
- Active ingredient: Somatropin
- Manufacturer: Pfizer
- Content: 12mg
- Form: Powder and solvent for solution for injection
- Package: Box of injection pen contains 12mg of somatropin
- Manufacturer: Pfizer
- Genotropin Drug Prices: COMMENT below for prices OR Click on the link: https://thuoclp.com/chatFB type “Genotropin”
Indications for the treatment of Genotropin drugs
T cheap you
- Growth disorders due to lack of growth hormone secretion (growth hormone deficiency, GHD) and growth disorders associated with Turner syndrome or chronic renal failure.
- Growth disturbance [current standard deviation height score (SDS) <- 2.5 and SDS <- 1 parental height adjustment in preterm infants with gestational age (SGA), with weight severe at birth and / or length below – 2 SD, who failed to show catch up growth rate [high speed (HV) SDS <0 in the last year] by 4 years or later.
- Prader-Willi syndrome (PWS), to improve growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.
Alternative therapy in adults with a pronounced growth hormone deficiency.
- Adult onset : Patients with severe growth hormone deficiency are associated with multiple hormone deficiency as a result of pathological hypothalamus or pituitary gland, and those with at least one lack of speech A pituitary hormone is not prolactin. These patients should undergo an appropriate dynamic test to diagnose or eliminate growth hormone deficiency.
- Childhood Onset: The patient is a growth hormone deficient in childhood as a result of congenital, hereditary, collected or idiopathic causes. Patients with early childhood GHD should be reevaluated for their ability to secrete growth hormone after completing longitudinal growth. In patients with a high likelihood of persistent GHD, i.e. a congenital cause or secondary GHD following a saddle / hypothalamus or offend disease, a growth factor-I type insulin (IGF-I) SDS <- 2 off growth hormone treatment for at least 4 weeks should be fully reviewed for evidence of GHD deeply.
All other patients will require IGF-I assays and a hormone stimulation test development.
Dosage and method of taking Genotropin
Injections should be injected under the skin and various sites to prevent lipoatrophy.
- Growth disturbance due to inadequate secretion of growth hormone in children: Generally a dose of 0.025 to 0.035 mg / kg body weight per day or 0.7-1.0 mg / m 2 body surface area per Date is recommended. Higher doses were used.
Where early childhood GHD persists into adolescence, treatment should be continued to achieve adequate somatic development (e.g. body composition, bone mass). For follow-up, achieving a normal peak bone mass is defined as a number of T> – 1 points (i.e. the standard for the average adult peak bone mass measured by dual absorption of X-ray energy taking into account sexual accounts and ethnicity) is one of the treatment goals throughout the transition period. For dosage instructions see the majority below.
- Prader-Willi syndrome, to improve growth and body composition in children: Generally a dose of 0.035 mg / kg of body weight per day or 1.0 mg / m 2 of body surface area each Date is recommended. The daily dose of 2.7 mg should not be exceeded. Treatment should not be used in children with a growth rate of less than 1 cm per year and near closing epiphyses.
- Growth disturbance due to Turner syndrome: A dose of 0.045-0.050 mg / kg of body weight per day or / m 1.4 mg 2 of body surface area per day is recommended.
- Growth disorders in chronic renal insufficiency: A dose of 0.045 to 0.050 mg / kg body weight per day (1.4 mg / m 2 body surface area per day) is recommended. Higher doses may be needed if the growth rate is too low. A dose adjustment may be needed after six months of treatment.
- Growth disorders in children Short born small for gestational age: A dose of 0.035 mg / kg body weight per day (1 mg / m 2 body surface area per day) is usually recommended until afternoon officially achieved (see section 5.1). The drug should be discontinued after the first year of treatment if the SDS velocity is below 1. Should the drug be discontinued if the velocity is <2 cm / year, and if confirmation is needed, the bone age is> 14 years (girl) or > 16 years (boy), corresponding to the closure of the bone growth plate.
- Growth hormone deficiency in adult patients: In patients who continue on growth hormone therapy after childhood GHD, the recommended dose to restart is 0.2-0.5 mg per day. The dose should be gradually increased or decreased according to individual patient requirements as determined by IGF-I levels.
- In adult patients starting GHD, treatment should begin with a low dose, 0.15-0.3 mg per day. The dose should be increased gradually according to the requirements of each patient as determined by the IGF-I concentration.
In both target cases, IGF-I levels should be within 2 SDS from the median adjustment age. Patients with normal IGF-I levels at the beginning of treatment should be given growth hormone up to an acute IGF-I into the upper range of normal, no more than 2 SDS. Clinical response and side effects may also be used as guidelines for dose titration. Admittedly, there are patients with GHD who do not normalize IGF-I levels despite a good clinical response, and therefore do not require an increase in dose. Maintenance dose rarely exceeds 1.0 mg per day. Women may require higher doses than men, which show an increased IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral estrogen replacements are being treated while men have been treated. The accuracy of growth hormone doses therefore needs to be monitored every 6 months. As normal physiological growth hormone production decreases with age, dose requirements are reduced. In patients older than 60 years, treatment should begin with a dose of 0.1-0.2 mg per day and should be increased gradually according to individual patient requirements. The minimum effective dose should be used. Maintenance dose in patients rarely exceeds 0.5 mg per day.
Contraindications of the drug Genotropin
Hypersensitivity to the active substance or any excipients.
Somatropin must not be used when there is any evidence of a tumor activity. Intracranial tumors must be inactive and antitumour treatment must be completed before starting growth hormone therapy. The drug should be discontinued if there is evidence of tumor growth
Genotropin should not be used for growth promotion in children with closed epiphyses.
Patients with acute critical distress complications after open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions should not be treated with Genotropin.
Warn before using Genotropin
Before you start using the medication, be sure to inform your doctor of any medical conditions or allergies you may have:
- a serious illness caused by lung failure, or complications from recent surgery, trauma or medical injury;
- active cancer
- diabetic eye problems (diabetic retinopathy);
- You are being treated for Prader-Willi syndrome and you are overweight or have serious respiratory problems (including sleep apnea).
Tell your doctor if you have ever had:
- Cancer: There may be an increased risk of tumor growth, both cancerous and non-cancerous, when growth hormone is used by childhood cancer survivors.
- Diabetes: Somatropin can cause an increase in blood sugar and glucose tolerance may change
- Scoliosis: People with scoliosis are at risk of worsening in their condition while taking somatropin.
- Underactive thyroid: If you have uncontrolled hypothyroidism, treatment with somatropin may not be as effective as it could be.
In some cases, Genotropin should not be used in children. Some brands of somatropin contain an ingredient that can cause serious side effects or death in young children or premature babies. Do not give this medication to a child without medical advice.
Some brands of somatropin are not expected to harm an unborn baby, including Genotropin, Onitrope, Saizen and Serostim.
It is not known whether certain other brands of somatropin will harm an unborn baby, including Humatrope, Norditropin, Nutropin, Zomacton and Zorbtive.
Tell your doctor if you are pregnant or plan to become pregnant.
It may not be safe to breast-feed while you are using this medication. Ask your doctor about any risks.
Pregnancy and lactation
Inadequate animal studies related to effects on pregnancy, embryofoetal development, childbirth or postnatal development. No clinical studies on exposed pregnancies are available. Therefore, somatropin contains products that are not recommended during pregnancy and potential women giving birth without contraception.
There are currently no clinical studies conducted with somatropin containing products in nursing women. It is not known whether somatropin is excreted into human milk, but the absorption of intact protein from the infant’s gastrointestinal tract is highly unlikely. Therefore caution should be exercised when somatropin contains products intended for nursing women.
Other drug interactions with Genotropin
Tell your doctor about all your other medicines, especially:
- birth control pills or hormone replacement therapy
- insulin or oral diabetes medication;
- a steroid (prednison, dexamethasone, methylprednisolone, and others).
This list is not complete. Other drugs may affect Genotropin, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.
Side effects of Genotropin
Get emergency medical help if you have signs of an allergic reaction: hives; shortness of breath; swelling of your face, lips, tongue or throat.
Serious respiratory problems may occur in patients with Prader-Willi syndrome using Genotropin. If you have Prader-Willi syndrome, call your doctor promptly if you have signs of lung or breathing problems such as difficulty breathing, coughing, or new or increased snoring.
Also call your doctor right away if you have:
- pain in your knees or hips, walking with your feet;
- ear pain, swelling, warmth or drainage;
- numbness or tingling in your wrist, hands or fingers;
- severe swelling or puffiness on your hands and feet;
- pain or swelling in your joints;
- Pancreatitis: relieves pain in the upper stomach spreading back, nausea and vomiting;
- high blood sugar: increased thirst, increased urination, dry mouth, fruity breath odor;
- increased pressure inside the skull: severe headache, tinnitus, dizziness, nausea, vision problems, pain behind the eyes; or
- signs of an adrenal gland problem: extreme weakness, severe dizziness, weight loss, changes in skin color, feeling very weak or tired.
Common side effects may include:
- pain, itching or change in the skin where the medicine is injected;
- swelling, rapid weight gain;
- muscle or joint pain;
- numbness or tingling;
- stomach pain, flatulence;
- headache, back pain;
- symptoms of cold or flu, stuffy nose, sneezing, sore throat, earache.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
Shelf life of the drug Genotropin
Proven stable chemical and physical use within 4 weeks at 2 ° C – 8 ° C.
From the microbiological point of view, once reconstituted, the product can be stored for 4 weeks at 2 ° C – 8 ° C. Other times in storage use and this condition is the responsibility of the user. .
Genotropin drug storage
Store in the refrigerator (2 ° C – 8 ° C), or for a maximum of 1 month equal to or lower than 25 ° C. Keep ink in two chambers / pre-fill pen in outer carton to protect from light.
Store in the refrigerator (2 ° C – 8 ° C). Do not freeze. Keep the two chamber ink / pre-fill pen in outer carton to avoid light. For storage conditions of renewable medicinal products, see section 6.3.
Special precautions for handling and other handling of the drug Genotropin
Only reconstitute the powder with the solvent provided.
Two-chamber ink : The solution is prepared by screwing the dispensing device or spraying device or GoQuick the pre-filled pen section together so that the solvent will be mixed with powder in the two-chamber cartridge. Gently dissolve the powder with a slow swirling motion. Do not shake vigorously, this may cause denaturation of the active substance. The regeneration solution is almost colorless or slightly milky. The reconstituted solution for injection is to be tested before use and only clear solutions without granules should be used.
Comprehensive instructions for the preparation and administration of re-released Genotropin products are given in the package leaflet, part 3, “Injecting genotropin” and in the relevant instructions for use provided with the device. used.
When using the injection equipment, it should be screwed before.
Handling instructions : Any unused product or waste material must be disposed of in accordance with local requirements. Empty GoQuick prefilled pens should never be refilled and must be properly discarded.
Drug Genotropin 12mg cost?
- Contact index-china 0933049874 (Zalo, FB, Viber) for a good price
- Instructions for using Genotropin 12mg GoQuick on Youtube
Drug Genotropin 12mg Somatropin 36IU where?
- Contact index-china 0933049874 (Zalo, FB, Viber)
Please COMMENT below for our answer to Genotropin 12mg (Somatropin 36IU) growth hormone
Contact index-china 0933049874 (Zalo / Facebook / Viber) purchase and sale of brand-name drugs in HCM City, Hanoi, Da Nang City, Can Tho, … nationwide:
Note: Information on Genotropin 12mg Somatropin article for the purpose of sharing knowledge for reference only, patients are not allowed to use the drug on their own, all information on drug use must be directed by a qualified physician.
Assoc.Prof.Dr. Tran Ngoc Anh is currently Hanoi Medical University Hospital, Associate Professor, Department of Internal Medicine, Gastroenterology and Head of Department of General-Uematology of Hanoi Medical University. Consulting doctor at ThuocLP Pharmacy.
Professional qualifications, Academic degrees – Education:
Graduated from General Practitioner System, Hanoi Medical University
Graduated with a Master degree in Internal Medicine, Hanoi Medical University
Graduated from the training program specialized in Gastrointestinal, Henri Mondor Institute Center, University of Paris 6, French Republic 1996-1997; 1999
Graduated from the training program specialized in Gastrointestinal, North Royal Sydney Hospital, Australia; 2002
Graduated from a training program specialized in chronic liver diseases, Pizza, Italy 2009
Graduated with a PhD in Gastrointestinal, Hanoi Medical University
Associate Professor, Gastroenterology, Hanoi Medical University
Training and Scientific Research:
Published more than 200 articles in domestic and international specialized journals
Editor of many monographs and participates in compiling 2 textbooks.
Guide many students and graduate students of Hanoi Medical University
Manager of many grassroots research projects
Certificate of Good Clinical Practice (GCP: 2012, 2015), Ministry of Health
Specialized certificates: General gastrointestinal endoscopy, Interventional gastrointestinal endoscopy, General gastrointestinal ultrasound, Interventional gastrointestinal ultrasound (Bach Mai BV), Chronic liver disease.